Multiple inhibitors targeting these molecules have been developed and patented, including various RIP1 inhibitors (such as Nec-1 and Nec-2), RIP1 and RIP3 inhibitors (such as GSKʹ840, GSKʹ843 or GSKʹ872), and MLKL inhibitors (such as necrosulfonamide) [78], which have shown good inhibitory effects on necroptosis and hepatic fibrosis at the animal and cell levels. This evidence concerns the gene MLKL and Hepatic fibrosis.